2025-10-30 - Analysis Report
Okay, let's analyze Procter & Gamble (PG) based on the provided data. Here's a structured report, as requested.

## Procter & Gamble (PG) Stock Analysis

**0) Report Summary (English with Numerical Highlights)**

Procter & Gamble (PG) shows a significant underperformance compared to the S&P 500 (VOO) over the period analyzed, with a large negative divergence in cumulative returns.  Recent price action shows a slight downward trend.  The company is considered a relatively safe investment based on its Market Risk Indicator (MRI) of 0.9. Analyst consensus leans towards a "Buy" rating.

**1) Performance vs. S&P 500 (VOO)**

*   **Ticker:** PG
*   **Company:** Procter & Gamble Co.
*   **Description:**  Procter & Gamble is a multinational consumer goods corporation that provides a wide range of branded products.

*   **Cumulative Return (PG):** 31.76%
*   **Cumulative Return (VOO):** 104.04%
*   **Divergence:**
    *   Max: 24.3
    *   Min: -69.4
    *   Current: -67.6
    *   Relative Divergence: 1.9

**Analysis:** PG has significantly underperformed the S&P 500 (VOO) over the analyzed period. The current divergence of -67.6 indicates a substantial difference in cumulative returns. The relative divergence of 1.9 suggests that the current divergence is near the lower end of its historical range.

| Year       | CAGR     | MDD   | Alpha   | Beta  | Cap(B) |
|------------|----------|-------|---------|-------|--------|
| 2015-2017  | 21.0%   | 7.9%  | -8.0%  | 0.0   | 214.7  |
| 2016-2018  | 9.0%    | 67.3% | -6.0%  | 0.1   | 214.7  |
| 2017-2019  | 24.0%   | 70.4% | 2.0%   | 0.3   | 291.8  |
| 2018-2020  | 27.0%   | 78.8% | 4.0%   | 0.4   | 325.1  |
| 2019-2021  | 41.0%   | 78.8% | -5.0%  | 0.5   | 382.1  |
| 2020-2022  | 13.0%   | 79.4% | 13.0%  | 0.6   | 354.1  |
| 2021-2023  | 26.0%   | 79.4% | 24.0%  | 0.4   | 342.4  |
| 2022-2024  | 9.0%    | 79.4% | -12.0% | 0.4   | 391.7  |
| 2023-2025  | -12.0%  | 80.1% | -81.0% | 0.2   | 351.4  |

**Analysis:** The table shows varying performance metrics over different periods. Key takeaways:

*   **CAGR:** Fluctuates significantly, with a negative return in the most recent period (2023-2025).
*   **MDD:** Maximum Drawdown is consistently high, indicating substantial potential for losses from peak to trough.
*   **Alpha:**  The alpha is largely negative, implying underperformance relative to a benchmark (likely the S&P 500).  The 2021-2023 period shows strong positive alpha. But recently very negative
*   **Beta:**  The beta values are low, suggesting PG is less volatile than the overall market.

**2) Recent Price Action**

*   **Last Price:** 150.395
*   **Last Market Data:** `{'price': 150.4, 'previousClose': 151.37, 'change': -0.64}`
*   **5-Day Moving Average:** 151.807
*   **20-Day Moving Average:** 150.9028
*   **60-Day Moving Average:** 154.3456

**Analysis:**  The current price is below the 5-day, 20-day, and 60-day moving averages, suggesting a recent downtrend.  The negative change from the previous close further supports this. However, the differences are not huge, suggesting a moderate downtrend rather than a crash.

**3) Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 49.00 (Neutral)
*   **PPO:** 0.2288
*   **Hybrid Signal:** Buy 100% (8 shares - Very Safe - MRI:0.90)
*   **Recent Relative Divergence Change:** -0.6 (Negative - Short-term decline)
*   **Expected Return:** 95.3% (Long-term, vs. S&P 500)

**Analysis:**

*   **MRI:** High MRI suggests a relatively safe investment.
*   **RSI:** The RSI is near 50, indicating a neutral momentum.
*   **PPO:** The PPO is slightly positive.
*   **Hybrid Signal:** The hybrid signal indicates that recent drop are not important
*   **Relative Divergence Change:** Recent trend suggests underperformance compared to the S&P 500.
*   **Expected Return:** The high expected return suggests potential for significant outperformance over the long term, though this contrasts with the recent underperformance and negative alpha values.

**4) Recent News & Significant Events**

*   **[2025-10-29]** 20 Years on Wall Street Taught Me: Dividend Blue-Chips You Never Sell (24/7 Wall St.)
*   **[2025-10-29]** Analyst Report: Procter & Gamble Co. (Argus Research)
*   **[2025-10-29]** Market Digest: CB, CHKP, NEE, GLW, PG, SYY, TMO, UL, XYL, KMI, PYPL, W, CARR (Argus Research)
*   **[2025-10-29]** JPMorgan Raises Procter & Gamble (PG) Price Target to $165, Keeps Neutral Rating (Insider Monkey)
*   **[2025-10-28]** United Dairy Farmers taps Gorilla Glue exec as new CEO as Brad Lindner retires (Cincinnati.com | The Enquirer)
*   **[2025-10-28]** Layoffs are piling up, raising worker anxiety. Here are some companies that have cut jobs recently (Associated Press Finance)

**Analysis:**

*   The news is mixed.  The articles highlighting dividend blue-chips and analyst reports are generally positive. JPMorgan's price target increase (though with a neutral rating) also suggests some optimism.
*   The article about layoffs, while not directly about PG, reflects broader economic concerns that could impact consumer spending and thus PG's revenue.
*   The Gorilla Glue CEO news is largely irrelevant.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.00)
*   **Opinions:** 22
*   **Target Price:** Avg: 168.73 / High: 186.00 / Low: 148.00
*   **Recent Rating Changes:** Not specified.

**Analysis:** The analyst consensus is "Buy," with a significant number of opinions considered. The average target price is above the current price, suggesting upside potential.

**5) Recent Earnings Analysis**

| 날짜         | EPS  | 매출        |
|--------------|------|-------------|
| 2025-10-24 | 2.00 | 22.39 B$   |
| 2025-04-24 | 1.58 | 19.78 B$   |
| 2025-01-22 | 1.94 | 21.88 B$   |
| 2024-10-18 | 1.65 | 21.74 B$   |
| 2025-10-24 | 1.65 | 21.74 B$   |

**Analysis:**

*   Earnings per share (EPS) and revenue have fluctuated over the past few quarters.
*   The most recent quarter (2025-10-24) shows a strong EPS of 2.00 and revenue of 22.39B$. The other 2025-10-24 looks like typo, and should be deleted

**6) Financial Information**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-06-30 | $20.89B     | 49.11%        |
| 2025-03-31 | $19.78B     | 50.98%        |
| 2024-12-31 | $21.88B     | 52.39%        |
| 2024-09-30 | $21.74B     | 52.06%        |
| 2024-06-30 | $20.53B     | 49.60%        |

| Quarter      | Equity        | ROE    |
|--------------|---------------|--------|
| 2025-06-30 | $52.01B      | 6.95%  |
| 2025-03-31 | $52.27B      | 7.21%  |
| 2024-12-31 | $51.17B      | 9.05%  |
| 2024-09-30 | $51.84B      | 7.64%  |
| 2024-06-30 | $50.29B      | 6.24%  |

**Analysis:**

*   **Revenue:** Revenue has fluctuated, but generally remains above $20 billion per quarter.
*   **Profit Margin:** Profit margins are consistently high, above 49%, indicating strong profitability.
*   **Equity:** Equity has remained relatively stable.
*   **ROE:** Return on Equity (ROE) has fluctuated, peaking in 2024-12-31.

**7) Overall Summary**

Procter & Gamble (PG) presents a mixed picture.

*   **Negatives:** Significant underperformance relative to the S&P 500 is a major concern, as is the recent downtrend in price. Negative alpha values suggest underperformance compared to a benchmark over many periods.
*   **Positives:**  The company is considered a relatively safe investment (high MRI). Analyst consensus is "Buy," with a positive average target price. Recent earnings were strong. Profit margins are consistently high. The long-term expected return is optimistic.
*   **Overall:** PG appears to be a relatively stable, profitable company, but it has significantly underperformed the broader market recently. The high expected return suggests that the market believes it is undervalued, and may have a long term growth expectation.

**Recommendation:**

While the long-term potential exists, investors should be aware of the recent underperformance. A cautious approach is warranted.  Further investigation into the reasons for the underperformance is recommended. A diversified portfolio is always advisable.
